HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US
See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month
Search
Where To Meet Us | Animal Health | Boehringer Ingelheim US
Click here to find out which pharmaceutical events Boehringer Ingelheim are attending over the next year and where you can get in touch with us.
Romy's Third-generation Japanese American Journey
Romy's Third-generation Japanese American Journey
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Pascal Haubert
After three months of interning with us, Pascal Haubert talks about the importance of taking responsibility, learning and mutual support.
Black innovators contribution to health & wellness throughout the years
Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Building lasting partnerships for a better future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Yamagata
With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
FDA accepts sNDA for children/adolescents with fibrosing ILD
U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes